Atomic AI

The end of 2023 is proving no different from the end of any other year, with venture capital firms and biopharmaceutical companies closing out a flurry of new VC funds and financings before December d

Few biopharmaceutical companies have announced $100m-plus venture capital mega-rounds so far this year and the ability to raise cash in 2023 generally has been described as muted relative to the recor